FRONT GENET 润色咨询

Frontiers in Genetics

出版年份:暂无数据 年文章数:9811 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:1.3% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2023-05-26 lialunxi 来自湖南省

    审稿速度:12.0 | 投稿命中率:25.0
    偏重的研究方向:肿瘤;纯生信
    经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2022-10-21 气管支气管

    10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况

    4

    展开4条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2022-10-21 yh2

    投稿50多天,还在编辑分配阶段,什么垃圾期刊

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2023-07-02 ms8000000152304602 来自浙江省

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2023-03-20 ms3000001292138274 来自广东省

    偏重的研究方向:基因
    经验分享:initial validation 3天了,一般多久啊😂

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2022-11-04 ms8000000784012918

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:生物信息学;非肿瘤
    经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript.

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2023-03-12 ms1000001827934077 来自吉林省

    心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!

    4

    展开4条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2023-03-20 ms3000001292138274 来自广东省

    投稿命中率:25.0
    偏重的研究方向:基因
    经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2023-02-23 vivi319 来自湖北省

    请问一下有没有一投稿还没外审就要求语言润色的?

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2139138, encodeId=c9872139138b0, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向:肿瘤;纯生信<br>经验分享:各位大神,我去年10月份投了篇纯生信的,然后审稿人意见回来已经是今年2月份了,大修之后2个审稿人同意了,但是从3月份到现在2个月过去了,还是在review finalized阶段,整整2个月,中间催了杂志社,但每次都说快了快了,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Fri May 26 10:32:31 CST 2023, time=2023-05-26, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2095109, encodeId=a20f209510938, content=10月20号晚上投了篇肺癌的纯生信,10月21号一大早直接拒稿,理由是不符合期刊发表要求。啥情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f4c5506339, createdName=气管支气管, createdTime=Fri Oct 21 08:53:04 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095143, encodeId=645120951434b, content=投稿50多天,还在编辑分配阶段,什么垃圾期刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7b55491270, createdName=yh2, createdTime=Fri Oct 21 11:17:23 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145958, encodeId=91f0214595858, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享:2023年6月 纯生信final decision结算被拒 大家如果还投可以犹豫一下啦, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a74f8320659, createdName=ms8000000152304602, createdTime=Sun Jul 02 14:31:16 CST 2023, time=2023-07-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2120586, encodeId=14f8212058655, content=偏重的研究方向:基因<br>经验分享:initial validation 3天了,一般多久啊😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 15:51:11 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2098543, encodeId=29dd209854338, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:生物信息学;非肿瘤<br>经验分享:审稿人2 rejected;审稿人3很专业,给了很多意见,finalized;审稿人4,finalized Date Updates 04 Nov 2022 Article accepted for publication. 03 Nov 2022 Corresponding Author re-submitted manuscript. Corresponding Author posted new comments in the Editor tab. 24 Oct 2022 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 4 is finalized. 13 Oct 2022 Review of Reviewer 3 is finalized. 11 Sep 2022 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15b68099957, createdName=ms8000000784012918, createdTime=Fri Nov 04 18:43:17 CST 2022, time=2022-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2119056, encodeId=c10721190564b, content=心太累了,投稿第二天被拒,理由是:This manuscript does not fulfill the standards established for the journal to be considered for publication。这个杂志一大堆文章都还不如我这个设计严谨呢,真有点儿被pua到!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cda8096239, createdName=ms1000001827934077, createdTime=Sun Mar 12 11:27:24 CST 2023, time=2023-03-12, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2120609, encodeId=397b2120609a4, content=投稿命中率:25.0<br>偏重的研究方向:基因<br>经验分享:用人的样品测序然后简单分析,第三天让我上传数据到指定的数据库,三分钟后就说建议转投内分泌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a48344813, createdName=ms3000001292138274, createdTime=Mon Mar 20 18:21:12 CST 2023, time=2023-03-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2116094, encodeId=ad3021160946f, content=请问一下有没有一投稿还没外审就要求语言润色的?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b92c107002, createdName=vivi319, createdTime=Thu Feb 23 12:34:19 CST 2023, time=2023-02-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2116489, encodeId=b5f72116489b1, content=偏重的研究方向:肿瘤;纯生信;基因<br>经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab055420094, createdName=少年宁, createdTime=Sun Feb 26 00:25:27 CST 2023, time=2023-02-26, status=1, ipAttribution=浙江省)]
    2023-02-26 少年宁 来自浙江省

    偏重的研究方向:肿瘤;纯生信;基因
    经验分享:投了一篇转录因子调控网络图的纯生信,第一个审稿人给了2323,主要要求要我补实验,别的都是统计学小问题,准备补个PCR,希望可以过!

    7

    展开7条回复
共500条页码: 2/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分